
Developing a surveillance system for HIV pre-exposure prophylaxis (PrEP) use in pregnancy in Malawi
The PrEP Pregnancy Registry provides prospective safety surveillance of pregnant women on PrEP within routine service delivery across Malawi. Guided by the WHO collaborative framework for antiretroviral safety in pregnancy, the Registry was established through a phased process involving the Malawi Ministry of Health, research and implementing partners. Initially implemented at five CAB-LA early-access facilities, it was refined with provider feedback and expanded to 30 additional facilities. The registry utilizes ScanForm, an AI-powered tool that uses optical character recognition technology to digitize and analyze handwritten data. Birth outcomes are measured using WHO’s harmonized pharmacovigilance indicators for maternal and infant birth outcomes.
Resource Details
- Study Type
- Pilot study
- Year
- 2026
- Population
- HIV-uninfected women, Pregnant Women
- Author
- Kamanga F, Squibb MA, Nyangulu W, Wu W, Chen J, Ngwira C, Drabko A, Garbarek W, Pomykala M, Bilicki D, Nakanga C, Masiye G, Chinula L, Mvalo T, Chagomerana MB, Matoga MM, Kumwenda W, Mkochi T, Matola E, Dias P, Mkochi N, Thonyiwa V, Nyirenda RK, Chewere L, Ozituosauka W, Jahn A, Nkhonjera J, Odek J, Hoege D, Schwartz S, Chauwa F, Dadabhai S, Phiri S, Rutstein SE, Herce M, Hoffman I, Allinder S, Holmes CB, Hosseinipour MC, Saidi F
- Source
- BMC Pregnancy and Childbirth
More Publications & Resources


Providing PrEP to Pregnant and Breastfeeding Women

Clinical Practice Guidelines for Providing PrEP for Pregnant and Breastfeeding Populations

Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis

PrEP and PEP Guidelines-Zambia

PrEP Lenacapavir Implementation Guidelines

Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)

Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP

Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics

Lenacapavir Provider Tools and Job Aids

PrEP Drug Interactions

